Fusen Pharmaceutical Company Limited (01652.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 4Aug 7Aug 12Aug 17Aug 20Aug 25Aug 28Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−59.0x

Market Cap

HKD 547.41M

MomentumView details →

1D Return

−5.73%

YTD Return

−7.50%

RSI (14)

22.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−59.0x

Market Cap

HKD 547.41M

RSI (14)

22.3

MomentumView details →

1D Return

−5.73%

YTD Return

−7.50%

ProfitabilityView details →

Gross Margin

41.71%

Net Margin

−34.28%

EBITDA Margin

2.33%

ROE (TTM)

−51.31%

ROA (TTM)

−14.28%

Asset Turnover

0.41x

GrowthView details →

Revenue YoY

−52.46%

EPS YoY

−66.71%

FCF YoY

+277.71%

Revenue CAGR 3Y

−17.78%

EPS CAGR 3Y

+93.88%

EBITDA YoY

−85.53%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.91x

Current Ratio

0.55x

Quick Ratio

0.46x

Div Yield

—

Div Rate

—

Div Growth 1Y

−65.57%

Financials snapshotView financials →

Revenue (TTM)

517.26M

Net Income (TTM)

−177.32M

Op. CF (TTM)

—

Latest newsMore news →

Fusen Pharmaceutical announced that four of its products were provisionally selected in China's 12th national centralized drug procurement tender on July 31, 2026.33d ago

Fusen Pharmaceutical's subsidiary Henan Fusen Pharmaceutical received approval from the National Medical Products Administration to market its drug Doxazosin Mesylate Extended-Release Tablets (trademark: Yijianping) for the treatment of mild-to-moderate hypertension and benign prostatic hyperplasia.54d ago

Similar companies

Kamada Ltd.KMDA Zhongzhi Pharmaceutical Holdings Limited03737.HK Evolus, Inc.EOLS Tilray Brands, Inc.TLRY Evotec SEEVO Aquestive Therapeutics, Inc.AQST Find similar companies →

Latest newsMore news →

Fusen Pharmaceutical announced that four of its products were provisionally selected in China's 12th national centralized drug procurement tender on July 31, 2026.33d ago Fusen Pharmaceutical's subsidiary Henan Fusen Pharmaceutical received approval from the National Medical Products Administration to market its drug Doxazosin Mesylate Extended-Release Tablets (trademark: Yijianping) for the treatment of mild-to-moderate hypertension and benign prostatic hyperplasia.54d ago